Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives Average Recommendation of “Buy” from Brokerages

Avadel Pharmaceuticals plc (NASDAQ:AVDL) has received an average rating of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $22.57.

AVDL has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Avadel Pharmaceuticals in a research note on Tuesday, April 9th. HC Wainwright raised their target price on Avadel Pharmaceuticals from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Craig Hallum upped their price target on Avadel Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Piper Sandler lifted their price objective on Avadel Pharmaceuticals from $18.00 to $23.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 5th. Finally, UBS Group began coverage on Avadel Pharmaceuticals in a report on Tuesday, February 6th. They set a “buy” rating and a $21.00 target price for the company.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP bought a new position in Avadel Pharmaceuticals in the third quarter worth $78,000. Quarry LP purchased a new position in Avadel Pharmaceuticals during the 4th quarter valued at about $120,000. Exencial Wealth Advisors LLC bought a new stake in Avadel Pharmaceuticals during the third quarter worth about $124,000. China Universal Asset Management Co. Ltd. boosted its stake in Avadel Pharmaceuticals by 349.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,327 shares of the company’s stock worth $146,000 after acquiring an additional 8,029 shares in the last quarter. Finally, Claro Advisors LLC bought a new position in shares of Avadel Pharmaceuticals during the first quarter valued at approximately $172,000. 69.19% of the stock is currently owned by institutional investors.

Avadel Pharmaceuticals Stock Performance

AVDL stock opened at $17.82 on Friday. The firm has a market cap of $1.61 billion, a P/E ratio of -8.74 and a beta of 1.60. The firm’s fifty day moving average is $15.74 and its 200 day moving average is $13.86. Avadel Pharmaceuticals has a 52 week low of $9.50 and a 52 week high of $18.85.

Avadel Pharmaceuticals (NASDAQ:AVDL) last announced its quarterly earnings data on Monday, March 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). The firm had revenue of $19.45 million during the quarter, compared to analysts’ expectations of $17.41 million. During the same quarter in the prior year, the business earned ($0.44) earnings per share. As a group, analysts forecast that Avadel Pharmaceuticals will post -0.46 EPS for the current year.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.